Mirati Therapeutics, Inc.
MRTXDrugs in Pipeline
11
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Adagrasib oral dose of 400 mg twice daily tablets Phase 2 Est. Readout
Estimated primary completion for Adagrasib oral dose of 400 mg twice daily tablets trial (NCT05609578) in Advanced NSCLC. Topline data typically follows completion by weeks to months.
SourcemFOLFOX6 Regimen
Advanced Colorectal Cancer
Sitravatinib
Clear Cell Renal Cell Carcinoma
MRTX849
Advanced Cancer
Adagrasib
Carcinoma, Non-Small-Cell Lung
AZD4547
Non-Small Cell Lung Cancer
MGCD516
Liposarcoma
Mocetinostat
Myelodysplastic Syndrome
MGCD0103
Lymphocytic Leukemia, Chronic
Adagrasib oral dose of 400 mg twice daily tablets
Advanced NSCLC
MGCD265
Non-Small Cell Lung Cancer
MRTX0902
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
mFOLFOX6 Regimen | Phase 3 | Advanced Colorectal Cancer | - | - |
Sitravatinib | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
MRTX849 | Phase 3 | Advanced Cancer | - | - |
Adagrasib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
AZD4547 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
MGCD516 | Phase 2 | Liposarcoma | - | - |
Mocetinostat | Phase 2 | Myelodysplastic Syndrome | - | - |
MGCD0103 | Phase 2 | Lymphocytic Leukemia, Chronic | - | - |
Adagrasib oral dose of 400 mg twice daily tablets | Phase 2 | Advanced NSCLC | - | - |
MGCD265 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
MRTX0902 | Phase 2 | Solid Tumor | - | - |
Non-Small Cell Lung Cancer
1 drug in this indication
Advanced NSCLC
1 drug in this indication
Lymphocytic Leukemia, Chronic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Mirati Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Mirati Therapeutics, Inc.'s (MRTX) pipeline across Phase 3, Phase 2. Its lead program is mFOLFOX6 Regimen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mirati Therapeutics, Inc.'s next FDA catalyst?→
Mirati Therapeutics, Inc.'s (MRTX) next tracked catalyst is a Phase 2 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRTX biotech catalysts?→
Add MRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mirati Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.